Philipp Huimann

Philipp Huimann
Neurologist Specialist
Neurologyen/specialities/neurology
See more specialists on
Madridmadrid
en/medical-staff/neurologist
A specialist in Neurology with a solid background in clinical neurology and a strong research profile in neuroimmunology. Of German origin and Spanish at heart, I completed my medical training at leading academic institutions such as Charité – Universitätsmedizin Berlin and my residency at Hospital Universitario Puerta de Hierro . I view clinical practice as a comprehensive process that combines diagnostic rigor, clinical research, and the application of new technologies, always from a humanistic and patient-centered approach. My clinical practice encompasses general neurology , specialist consultations, and hospital care, with a particular interest in neuroimmunological diseases, multiple sclerosis, and inflammatory disorders of the central nervous system. I combine clinical practice with active participation in international multicenter clinical trials and translational research projects.
Key information
- Latest Publication:3-Iodothyronamine increases TRPM8 activity in immortalized human corneal epithelial cells
Professional Details
Centro Médico Quirónsalud Valdebebas
SPECIALIST PHYSICIAN NEUROLOGY
September 2023 -
Present
Universidad Europea
Assistant Professor
March 2026 - December 9999
Hospital Universitario Puerta de Hierro
Neuroimmunology Research Fellow
January 2026 - December 9999
Hospital Universitario Vithas Madrid La Milagrosa - Instituto de Neurosciencias
Specialist doctor
January 2026 - December 9999
Hospital Universitario del Henares
Specialist doctor
October 2025 - December 9999
Hospital Universitario Puerta de Hierro Majadahonda
Specialist doctor
July 2025 - January 2026
Hospital Italiano de Buenos Aires
External rotation
October 2024 - November 2024
Hospital Can Misses
External rotation
September 2024 - September 2024
Hospital Universitario Puerta de Hierro Majadahonda
Neurology Resident Physician
July 2021 - July 2025
Study
Degree in Medicine
Charité Universitätsmedizin Berlin
2020
Specialized Healthcare Training
Neurologist
Another qualification
Neuroimmunology: Beyond Multiple Sclerosis
Another qualification
Biomarkers in MS
Another qualification
Assessment and Therapy in Parkinson's Disease
Another qualification
Bioethics in the hospital for residents
Another qualification
MDS – Classification and Approach to Movement Disorders
Another qualification
11th Edition INSIDE OUT MS
Another qualification
Neurodegenerative Diseases – Parkinson's and Alzheimer's
Another qualification
Urgent seizures and status epilepticus
Another qualification
Epilepsy Experience
Another qualification
OCT for neurologists
Another qualification
Artificial Intelligence in Neurology
Another qualification
MDS – Eye Movement Disorders
Another qualification
Interdisciplinary care in epilepsy – seizure code
Another qualification
Epilepsy Residents Forum
Another qualification
New Advances and Challenges in Multiple Sclerosis – 10th Edition
Another qualification
NEURORECORDINGS in Alzheimer's, Movement Disorders and Epilepsy
Another qualification
Course in Semiology of Movement Disorders
Another qualification
MDS – Assessment of Movement Disorders
Another qualification
ECTRIMS
Assistant Professor at Charité – Universitätsmedizin Berlin
Charité – Universitätsmedizin Berlin
July 2014 - July 2017
LTS17043: Extension study of tolebrutinib in progressive MS – Phase III
Sanofi
O’Hand [WA40404]: Ocrelizumab in primary progressive MS – Phase III
F. Hoffmann-La Roche Ltd.
OCARINA II [CN42097]: Subcutaneous vs intravenous Ocrelizumab – Phase III
F. Hoffmann-La Roche Ltd.
GAVOTTE [BN42083]: Ocrelizumab at high doses in primary progressive MS – Phase IIIb
F. Hoffmann-La Roche Ltd.
AC-058B202/M: Ponesimod in relapsing-remitting MS – Phase III
ACTELION Pharmaceuticals Ltd.
RPC01-3001: Ozanimod in remitting MS – Phase III
Celgene International II Sàrl
COMB157G2399 [ALITHIOS]: Ofatumumab Extension Study in Remitting MS – Phase III
Novartis Pharmaceuticals S.A.
PERSEUS [EFC16035]: Tolebrutinib in primary progressive MS – Phase III
Sanofi
OPERA I [WA21092]: Ocrelizumab vs Interferon beta-1a in relapsing-remitting MS – Phase III
F. Hoffmann-La Roche Ltd.
OLERO [MN43964]: Ocrelizumab Extension Study – Phase IIIb
F. Hoffmann-La Roche Ltd.
MS700568_0157 [Magnify MS]: Observational study in patients treated with interferon beta – Phase IV
Merck Healthcare KGaA
MS200527_0082: Evobrutinib vs Teriflunomide in relapsing MS – Phase III
Merck Healthcare KGaA
HERCULES [EFC16645]: Tolebrutinib in non-relapsed progressive secondary MS – Phase III
Sanofi
CBAF312A2304: Siponimod in relapsing-remitting secondary progressive MS – Phase III
Novartis Pharmaceuticals S.A.
CLOU064C12301: Remibrutinib vs Teriflunomide in remitting MS – Phase III
Novartis Pharmaceuticals S.A.
3-Iodothyronamine increases TRPM8 activity in immortalized human corneal epithelial cells
Article
Usefulness of the water-bath technique in cutaneous ultrasound
Article
German
Native
Spanish
C2
English
C1
Make an appointment with this professional
Vídeos de
Consulta el contenido multimedia de este profesional.
Hospitals
Book an appointment now at one of our hospitals.
Articles on
Browse the latest articles on Tu canal de salud.

¿No tienes seguro de salud?
Con nuestros Planes de Salud Quirónsalud Connect tendrás un médico de medicina general todos los días las 24 horas. Y además gestor personal y medición facial de constantes vitales.




